Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy

a systematic review, meta-analyses, and meta-regression

Reem Waziry, Behzad Hajarizadeh, Jason Grebely, Janaki Amin, Matthew Law, Mark Danta, Jacob George, Gregrory J. Dore

Research output: Contribution to journalArticle

181 Citations (Scopus)

Abstract

Background & Aims: The risk of hepatocellular carcinoma (HCC) occurrence or recurrence following direct-acting antiviral (DAA) hepatitis C virus (HCV) therapy remains unclear. The aims of this study were to compare the rate of HCC occurrence in patients with HCV-related cirrhosis, following DAA vs. interferon (IFN)-based cure, and to compare the rate of HCC recurrence in patients who received curative HCC treatment, following DAA vs. IFN-based cure. Methods: A search was conducted for reports published between January 2000 and February 2017. Studies were included if they assessed HCC outcomes by type and response to HCV therapy. Random-effects meta-analyses were undertaken to determine a combined estimate of HCC incidence rate per 100/person-years (py) among patients with a sustained virological response (SVR). Results: A total of 41 studies (n = 13,875 patients), including 26 on HCC occurrence (IFN = 17, DAA = 9; prospective = 19, retrospective = 5, retrospective-prospective = 2), and 17 on HCC recurrence (IFN = 7, DAA = 10; prospective = 11, retrospective = 5 and retrospective-prospective = 1) were included. In studies assessing HCC occurrence, average follow-up was shorter (1.0 vs. 5.5. years), and average age older (60 vs. 52. years) in DAA studies. In studies assessing HCC recurrence, average follow-up was shorter (1.3 vs. 5.0. years), but average age similar (64 vs. 66. years) in DAA studies. HCC occurrence was 1.14/100 py (95% CI 0.86-1.52) and 2.96/100 py (95% CI 1.76-4.96) in IFN and DAA studies respectively. HCC recurrence was 9.21/100 py (95% CI 7.18-11.81) and 12.16/100 py (95% CI 5.00-29.58) in IFN and DAA studies respectively. In meta-regression adjusting for study follow-up and age, DAA therapy was not associated with higher HCC occurrence (RR 0.68; 95% CI 0.18-2.55; p = 0.55) or recurrence (RR 0.62, 95% CI 0.11-3.45, p = 0.56). Conclusion: There is no evidence for differential HCC occurrence or recurrence risk following SVR from DAA and IFN-based therapy. Lay summary: The risk of hepatocellular carcinoma (HCC) occurrence or recurrence following direct-acting antiviral (DAA) hepatitis C virus (HCV) therapy remains unclear. We conducted a meta-analysis to compare occurrence and recurrence of HCC in patients receiving either DAA or interferon (IFN) therapy. There is no evidence that HCC occurrence or recurrence is different between patients receiving DAA or IFN therapy. © 2017 European Association for the Study of the Liver.
Original languageEnglish
Pages (from-to)1204-1212
Number of pages9
JournalJournal of Hepatology
Volume67
Issue number6
DOIs
Publication statusPublished - Dec 2017

Keywords

  • hepatocellular carcinoma
  • occurrence
  • recurrence
  • epidemiology
  • chronic hepatitis C virus
  • Recurrence
  • Chronic hepatitis C virus
  • Hepatocellular carcinoma
  • Epidemiology
  • Occurrence

Fingerprint Dive into the research topics of 'Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression'. Together they form a unique fingerprint.

Cite this